SELLAS Life Sciences Group, Inc. (SLS) Hits All-Time Low

June 29, 2018 - By Sarah Harris

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) reached all time low on Jun, 29 touching $3.24. Our target is $3.08. It was reported by The company has $21.56M market cap. At $3.08 stock target, the company valuation changes by $1.08 million less.

The stock decreased 8.22% or $0.29 during the last trading session, hitting $3.24.SELLAS Life Sciences Group, Inc. has volume of 137,647 shares. Since June 29, 2017 SLS has declined 71.31% and is downtrending. SLS underperformed by 83.88% the S&P 500.

For more SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) news brought out briefly go to:,,, or The titles are as follows: “40 Stocks Moving In Tuesday’s Mid-Day Session” brought out on June 26, 2018, “Mid-Morning Market Update: Markets Open Higher; Lennar Tops Q2 Estimates” on June 26, 2018, “Your Daily Pharma Scoop: Recent IPO And Offerings Review” with a publish date: May 31, 2018, “Mid-Morning Market Update: Markets Open Higher; Abercrombie & Fitch Beats Q1 Expectations” and the last “SELLAS Life Sciences Announces Proposed Public Offering of Common Stock” with publication date: June 26, 2018.

SELLAS Life Sciences Group, Inc., a development-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications.The firm is valued at $21.56 million. The company's lead product candidate is galinpepimut-S, a cancer immunotherapeutic agent for the treatment of hematologic cancers and solid tumor indications, including acute myeloid leukemia, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, immune combo, and chronic myelogenous leukemia.Currently it has negative earnings. It also develops NEUVAX, which is in Phase II clinical trial for the treatment of breast cancer; and Anagrelide controlled release, which has completed various clinical trials for the treatment of thrombocythemia.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.